Completion report on merger, etc. (merger)

What happened

Completion Report on Merger, etc. (Merger), Form 6.0 GL Pharm Tech Co., Ltd. To: Governor of the Financial Supervisory Service July 31, 2026 Company name: GL Pharm Tech Co., Ltd. Representative Directors: Jin Seong-pil, Kim Yong-il Head office address: Room 210, Building B, 46 Dallaenae-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do Phone: 031-602-5220 Website: http://www.glpt.co.kr Preparer: (Title) CCO; (Name) Choi Jeong-min; (Phone) 031-602-5220

I. Schedule Merger board resolution (*1): May 28, 2026; in lieu of general meeting Announcement of record date for determining shareholders: May 28, 2026; announced on company website Merger contract date: June 1, 2026; - Record date for determining voting-rights shareholders (*2): June 12, 2026; - Small-scale merger announcement: June 12, 2026; announced on company website Start of period for receiving merger-objection notices: June 12, 2026; - End of period for receiving merger-objection notices: June 26, 2026; - Board resolution approving the merger: June 29, 2026; in lieu of general meeting Creditor objection announcement: June 30, 2026; announced on company website Merger effective date: July 31, 2026; - Board resolution for merger completion report: July 31, 2026; in lieu of general meeting Merger completion report announcement (*3): July 31, 2026; announced on company website Scheduled merger registration date: August 4, 2026; scheduled registration filing date

(*1) The surviving company, GL Pharm Tech Co., Ltd., proceeded with a small-scale merger under Article 527-3 of the Commercial Act; shareholders' meeting approval for the merger is replaced by a board resolution, and dissenting shareholders are not granted appraisal rights. (*2) The record date for determining voting-rights shareholders refers to the record date for shareholders entitled to raise objections to the small-scale merger. (*3) The merger completion report meeting was replaced, under Article 526 of the Commercial Act, by an announcement based on a board resolution.

II. Changes in Major Shareholder Equity - The surviving company, GL Pharm Tech Co., Ltd., owns 100% of the shares of the dissolving company, GL Pharma Co., Ltd., and resolved to merge at a no-capital-increase ratio of 1.0000000:0.0000000. GL Pharm Tech Co., Ltd. will not issue new shares as a result, and there is no change in the equity of the largest shareholder, etc.

III. Exercise of Appraisal Rights - Because this merger proceeds under the small-scale merger procedure of Article 527-3 of the Commercial Act, appraisal rights were not granted. - Merger-objection notices were accepted from June 12, 2026 to June 26, 2026 under Article 527-3 of the Commercial Act; 149 shareholders submitted objection notices, representing 909,466 shares (1.17% of total shares issued).

IV. Creditor Protection - The surviving company, GL Pharm Tech Co., Ltd., and the dissolving company, GL Pharma Co., Ltd., each issued a creditor-objection announcement and demand notice on June 30, 2026; no creditor submitted an objection by the expiration of the creditor-objection period on July 30, 2026. No decision has been made to repay debts or provide substantial collateral in connection with this matter.

V. Status of Related Litigation - As of the date of this report, no lawsuit has been filed in connection with this merger that could affect its validity.

VI. Matters Concerning New Share Allotment, etc. - Because this is a no-capital-increase merger that does not issue merger new shares (ratio 1.0000000:0.0000000), no new shares will be issued, and there is no separate merger cash consideration.

VII. Summary Financial Information Before and After [Merger, etc.] (as of March 31, 2026) (unit: KRW) Category: Before merger - GL Pharm Tech Co., Ltd. (surviving) / GL Pharma Co., Ltd. (dissolving); After merger (estimated) - GL Pharm Tech Co., Ltd. Current assets: 9,525,887,723 / 14,660,357,000 / 21,573,553,113 Non-current assets: 20,739,914,074 / 17,137,499,712 / 27,029,877,123 Total assets: 30,265,801,797 / 31,797,856,712 / 48,603,430,236 Current liabilities: 7,134,259,842 / 17,952,635,802 / 22,640,342,445 Non-current liabilities: 962,524,666 / 5,177,546,381 / 6,164,229,354 Total liabilities: 8,096,784,508 / 23,130,182,183 / 28,804,571,799 Capital stock: 7,754,900,600 / 6,227,270,000 / 7,754,900,600 Capital surplus: 34,299,274,952 / 6,927,025,438 / 34,299,274,952 Other equity: 14,094,582 / - / 14,094,582 Accumulated other comprehensive income (loss): (4,292,010) / 7,052,994,000 / - Retained earnings (deficit): (19,894,960,835) / (11,539,614,909) / (22,269,411,697) Total equity: 22,169,017,289 / 8,667,674,529 / 19,798,858,437 Total liabilities and equity: 30,265,801,797 / 31,797,856,712 / 48,603,430,236

Note 1: The above summary statement of financial position is based on the separate (non-consolidated) statements of financial position of GL Pharm Tech Co., Ltd. and GL Pharma Co., Ltd. as of March 31, 2026, the most recent financial statements available at the filing date, and may differ from the statement to be prepared as of the actual merger effective date (July 31, 2026). Note 2: The above post-merger financial statements have not been audited (reviewed) by an external auditor and may change based on the external auditor's audit (review).